AbbVie Inc

ABBV08 Dec 2024
Healthcare
$176
+0.00 (+0.01%)
Lowest Today
$174.16
Highest Today
$176.74
Today’s Open
$176
Prev. Close
$176.17
52 Week High
$207.32
52 Week Low
$144.86
To Invest in AbbVie Inc

AbbVie Inc

Healthcare
ABBV08 Dec 2024
+0.00 (+0.01%)
1M
3M
6M
1Y
5Y
Low
$174.16
Day’s Range
High
$176.74
174.16
52 Week Low
$144.86
52-Week Range
52 Week High
$207.32
144.86
1 Day
-
1 Week
-3.06%
1 month return
-11.65%
3 month return
-10.28%
6 month return
+3.39%
1 Year return
+18.1%
3 Years return
+44.57%
5 Years return
+104%
10 Years return
-
Institutional Holdings
Vanguard Group Inc
9.71
BlackRock Inc
7.72
State Street Corp
4.47
Vanguard Total Stock Mkt Idx Inv
3.15
JPMorgan Chase & Co
2.95
Vanguard Institutional 500 Index Trust
2.65
Morgan Stanley - Brokerage Accounts
2.19

Market Status

Fundamentals
Market Cap
311352.39 mln
PB Ratio
51.62
PE Ratio
61.39
Enterprise Value
375146.45 mln
Total Assets
134711 mln
Volume

Company Financials

Fund house & investment objective

Company Information
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Organisation
AbbVie Inc
Employees
50000
Industry
Drug Manufacturers - General
CEO
Mr. Robert A. Michael
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step